Skip to main content
. Author manuscript; available in PMC: 2008 Oct 28.
Published in final edited form as: Neurology. 2004 Mar 9;62(5):778–782. doi: 10.1212/01.wnl.0000113749.77217.01

Table 2.

Immunologic associations: Antibodies to Zic4, Hu, and CRMP5 proteins

Associations Anti-Zic4+ Anti-Hu+ Anti-CRMP5+
PND with SCLC or neuroendocrine tumors* (n = 167) 49† 125‡ 18§
PND with other tumors (n = 48) 0 0 0
Cancer without PND
 SCLC (n = 74) 12† 14‡ 7§
 Other (n = 34) 0 0 0
Miscellaneous neurologic disorders without cancer (n = 155) 0 0 0
Normal individuals (n = 20) 0 0 0
*

Overlap of antibodies: 9 patients had Zic4 + Hu + CRMP5 antibodies; 29 patients had Zic4 and Hu antibodies; 2 patients had Zic4 and CRMP5 antibodies; 5 patients had Hu and CRMP5 antibodies.

†

Association of anti-Zic4 antibodies and PND, p = 0.031.

‡

Association of anti-Hu antibodies and PND, p < 0.001.

§

Association of anti-CRMP5 antibodies and PND, p = 0.75.

PND = paraneoplastic neurologic disorders; SCLC = small-cell lung cancer.